BridgeBio Oncology Therapeutics Inc. - ROE
BBOT
Price:
$4.89
Market Cap:
$391.72M
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, ...[Read more]
Industry
Biotechnology
IPO Date
2025-08-12
Stock Exchange
NASDAQ
Ticker
BBOT
PE Ratio
[-2.44]
ROE
[-46.90%]
Current Ratio
[4.69]
Dividend Yield
[0%]
Enterprise Value
[340.17M]
Dividend History
The ROE as of September 2026 (TTM) for BridgeBio Oncology Therapeutics Inc. (BBOT) is -46.90%
According to BridgeBio Oncology Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is -46.90%. This represents a change of 288.90% compared to the average of -12.06% of the last 4 quarters.
BridgeBio Oncology Therapeutics Inc. (BBOT) Historical ROE (quarterly & annually)
How has BBOT ROE performed in the past?
The mean historical ROE of BridgeBio Oncology Therapeutics Inc. over the last ten years is 20.39%. The current -46.90% ROE has changed -100.23% with respect to the historical average. Over the past ten years (40 quarters), BBOT's ROE was at its highest in in the December 2023 quarter at 65.59%. The ROE was at its lowest in in the June 2026 quarter at -17.47%.
Average
20.39%
Median
16.09%
Minimum
-39.36%
Maximum
101.78%
BridgeBio Oncology Therapeutics Inc. (BBOT) ROE by Quarter and Year
Discovering the peaks and valleys of BridgeBio Oncology Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 632.45%
Maximum Annual ROE = 101.78%
Minimum Annual Increase = -100.04%
Minimum Annual ROE = -39.36%
| Year | ROE | Change |
|---|---|---|
| 2025 | -32.61% | -17.15% |
| 2024 | -39.36% | -100.04% |
| 2023 | 101.78% | 632.45% |
| 2022 | 16.09% | -93.19% |
BridgeBio Oncology Therapeutics Inc. (BBOT) Average ROE
How has BBOT ROE performed in the past?
The current ROE of BridgeBio Oncology Therapeutics Inc. (BBOT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
33.90%
5-year avg
20.39%
10-year avg
20.39%
BridgeBio Oncology Therapeutics Inc. (BBOT) ROE vs. Peers
How is BBOT’s ROE compared to its peers?
BridgeBio Oncology Therapeutics Inc.’s ROE is greater than Mind Medicine (MindMed) Inc. (-85.23%), less than UroGen Pharma Ltd. (81.78%), greater than Nurix Therapeutics, Inc. (-76.09%), greater than Xencor, Inc. (-28.66%), greater than Kodiak Sciences Inc. (-273.23%), less than AnaptysBio, Inc. (442.91%), less than Phathom Pharmaceuticals, Inc. (25.70%), greater than Oculis Holding AG (-42.92%), greater than Tango Therapeutics, Inc. (-25.74%), greater than Septerna Inc (-6.31%),
| Company | ROE | Market cap |
|---|---|---|
| -85.23% | $1.56B | |
| 81.78% | $2.14B | |
| -76.09% | $2.65B | |
| -28.66% | $1.82B | |
| -273.23% | $2.06B | |
| 442.91% | $1.63B | |
| 25.70% | $626.98M | |
| -42.92% | $570.55M | |
| -25.74% | $3.82B | |
| -6.31% | $1.78B |
Build a custom stock screener for BridgeBio Oncology Therapeutics Inc. (BBOT) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BridgeBio Oncology Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
BridgeBio Oncology Therapeutics Inc. (BBOT) and other stocks custom spreadsheet templates
The easiest way to analyze a company like BridgeBio Oncology Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is BridgeBio Oncology Therapeutics Inc.'s ROE?
How is the ROE calculated for BridgeBio Oncology Therapeutics Inc. (BBOT)?
What is the highest ROE for BridgeBio Oncology Therapeutics Inc. (BBOT)?
What is the 3-year average ROE for BridgeBio Oncology Therapeutics Inc. (BBOT)?
What is the 5-year average ROE for BridgeBio Oncology Therapeutics Inc. (BBOT)?
How does the current ROE for BridgeBio Oncology Therapeutics Inc. (BBOT) compare to its historical average?